Showing 20 of 62 recruiting trials for “marginal-zone-lymphoma”
RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
👨⚕️ Yucai Wang, Academic and Community Cancer Research United📍 2 sites📅 Started Jan 2024View details ↗
The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and Radiotherapy
👨⚕️ Jun Shi, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University📍 1 site📅 Started Nov 2023View details ↗
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
👨⚕️ Catherine THIEBLEMONT, Pr, Lymphoma Study Association📍 48 sites📅 Started Sep 2023View details ↗
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
👨⚕️ Kelly McConnell, PhD, Memorial Sloan Kettering Cancer Center📍 2 sites📅 Started Jul 2023View details ↗
RecruitingNCT06241729 ↗
Prospective Observational Study of Diffuse Large-cell B Lymphoma
Clinical Study of OR for Second-line Treatment of Refractory MZL
RecruitingNCT06073938 ↗
Compassionate Use Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement
RecruitingNCT05506410 ↗
A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma
👨⚕️ Zhang Mingzhi Zhang, The First Affiliated Hospital of Zhengzhou University📍 1 site📅 Started Aug 2022View details ↗
Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.
👨⚕️ Marco Ladetto, S.C. Ematologia - A.S.O. "SS Antonio e Biagio e Cesare Arrigo" di Alessandria📍 21 sites📅 Started Mar 2022View details ↗
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
👨⚕️ Stephen D Smith, Academic and Community Cancer Research United📍 7 sites📅 Started Aug 2021View details ↗
Avo In R/R And Previously Untreated MCL
MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma
Phase Ib Clinical Study of Keynatinib
Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
RecruitingNCT03494296 ↗
A Prospective Study of Low-dose Decitabine Combined With COP Regimen in the Treatment of Relapsed and Refractory DLBCL
👨⚕️ Shuye Wang, PhD, First Affiliated Hospital of Harbin Medical University📍 1 site📅 Started Mar 2018View details ↗
ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma
👨⚕️ Martin Dreyling, Prof., Klinikum der Universität München📍 112 sites📅 Started Jul 2016View details ↗
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →